A recent report highlights the detrimental effects of Brexit on British cancer patients, with rising costs and increased red tape obstructing access to life-saving drugs and clinical trials. As the number of cancer diagnoses increases and Europe benefits from advancements in treatment, researchers warn that the UK is falling behind. The report indicates that the costs associated with importing cancer medications have surged dramatically, making it challenging for NHS doctors to offer patients innovative therapies previously accessible through international collaboration. This situation underscores the urgent need for improved global cooperation.
Brexit costs and red tape are denying British cancer patients life-saving drugs, a damning report warns, indicating the negative impact of post-Brexit regulations.
Five years post-Brexit, analysis shows Britons with cancer face significant barriers in accessing new treatments, unlike patients across Europe enjoying advancements.
Collection
[
|
...
]